Sales Through Retail Pharmacies (Twelve months to November 2010)*
NORTH AMERICA $243.0 billion up 3%
U.S.A. $223.8 billion up 3%
CANADA $19.3 billion up 3%
EUROPE (TOP 5) $106.9 billion up 1%
GERMANY $34.9 billion up 3%
FRANCE $28.1 billion up 0%
ITALY $15.8 billion up 0%
SPAIN $14.5 billion up 0%
UK $13.6 billion up 2%
JAPAN (including hospitals) $85.1 billion up 1%
CHINA (hospital) $31.6 billion up 23%
LATIN AMERICA (TOP 4) $35.0 billion
BRAZIL $17.2 billion up 20%
MEXICO $7.7 billion up 1%
VENEZUELA $6.2 billion up 31%
ARGENTINA $3.9 billion up 25%
AUSTRALIA/NZ $9.6 billion up 6%
The top 5 therapy classes at ATC3 level in the 12 months to November 2010 were:
1. C10A – Cholesterol & trigly. regulators
2. A2B - Antiulcerants
3. N5A - Antipsychotics
4. N6A – Antidepressants & mood stabilisers
5. C9C – Angioten-II Antag, Plain
The top 5 products in the 12 months to November 2010 were:
1. Lipitor
2. Plavix
3. Nexium
4. Seretide
5. Crestor
The top 5 corporations in the 12 months to November 2010 were:
1. Pfizer
2. Novartis
3. AstraZeneca
4. Merck & Co
5. GlaxoSmithKline
